Thursday 16 October, 2025
Introduction Current treatment of latent tuberculosis infection (LTBI) include combined rifapentine (RFT) and isoniazid daily treatment for one month (1HP)…
Read morePoster: Clinical Applications
Using Bayesian Modelling to Evaluate the Effect of a Neonatal Vancomycin Loading Dose on Therapeutic Target Attainment in a Low-Middle Income Country
Thursday 16 October, 2025
Introduction: Vancomycin, a glycopeptide antibiotic, has served as a cornerstone in treating hospital-acquired Gram-positive infections for over five decades. Recommended for…
Read morePopulation pharmacokinetic and pharmacodynamic analysis of granulocyte colony-stimulating factor (G-CSF) to optimize dose and timing for harvesting CD34+ cells
Thursday 16 October, 2025
Objectives: Filgrastim is a well-known granulocyte colony-stimulating factor (G-CSF), a cytokine for the maturation and mobilization of bone marrow neutrophils….
Read moreUnderdosing imipenem in patients with renal insufficiency: global clinical data-driven pharmacokinetic/pharmacodynamic study
Thursday 16 October, 2025
Objectives: Currently, population pharmacokinetic (popPK) models for imipenem in critically ill patients are available. However, they lack a good representation of…
Read moreA model-informed framework for prioritizing pharmacogenomic drug-gene interactions in an Asian context for chemotherapy
Thursday 16 October, 2025
Objectives: Despite making up more than 60% of the world’s population, Asian genomes are under-characterized. A large-scale whole genome sequencing…
Read moreTowards MIPD of Linezolid: External Evaluation of Population Pharmacokinetic Models
Thursday 16 October, 2025
Objectives: Overdosing of linezolid increases the risk of adverse events such as thrombocytopenia, lactic acidosis, or neuropathy, while underdosing may…
Read moreModel-informed dose optimization of mycophenolic acid in pediatric renal transplant patients
Thursday 16 October, 2025
Introduction: Mycophenolic acid (MPA), the active compound of the prodrug mycophenolate mofetil (MMF), is a pharmacotherapeutic cornerstone to prevent allograft…
Read morePopulation pharmacokinetic modelling of oral ruxolitinib: a real-world prospective observational study
Thursday 16 October, 2025
Objectives: Ruxolitinib is a small molecule targeting JAK1 and JAK2 proteins and used orally for the treatment of myeloproliferative disorders, such…
Read moreInvestigating Alternative Daily Dose Regimens for Bedaquiline in Treatment of Multidrug-Resistant Tuberculosis using an Interactive Shiny Application
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) remains a major global health concern, especially multidrug-resistant (MDR) TB [1]. Bedaquiline (BDQ), is an effective drug for…
Read morePharmacokinetic model-informed precision dosing of natalizumab in Multiple Sclerosis
Thursday 16 October, 2025
Introduction: Natalizumab is highly effective in treating relapsing-remitting multiple sclerosis. However, the standard intravenous treatment interval of 4 weeks may…
Read more